Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition

Cancer Biology and Therapy

Volumn 14, Issue 3, 2013, Pages 237-245

  Ai, Midan ^a,b   Liang, Ke ^a   Lu, Yang ^a   Qiu, Songbo ^a   Fan, Zhen ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; Brk; EMT; HER2; Src; STAT3; Survival

Indexed keywords

BREAST TUMOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 6; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CELL MIGRATION; CELL SURVIVAL; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; PHENOTYPE; PROTEIN PROTEIN INTERACTION;

BREAST CANCER; BRK; EMT; HER2; SRC; STAT3; SURVIVAL;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MCF-7 CELLS; MICE; NEOPLASM PROTEINS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTOR, ERBB-2; STAT3 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS;

EID: 84874858785     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.23295     Document Type: Article

References (43)

1. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5:591-602; PMID:16056258; http://dx.doi.org/10. 1038/nrc1670. (Pubitemid 41081385)
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82; PMID:3798106; http://dx.doi.org/ 10.1126/science.3798106. (Pubitemid 17231334)
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244:707-12; PMID:2470152; http://dx.doi.org/10.1126/science. 2470152. (Pubitemid 19147683)
4. Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2001; 6:393-406; PMID:12013529; http://dx.doi.org/10.1023/A:1014730829872.
5. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61(Suppl 2):1-13; PMID:11694782; http://dx.doi.org/10.1159/000055396. (Pubitemid 33033419)
6. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011; 17:461-9; PMID:21399647; http://dx.doi.org/ 10.1038/nm.2309.
7. Barker KT, Jackson LE, Crompton MR. BRK tyrosine kinase expression in a high proportion of human breast carcinomas. Oncogene 1997; 15:799-805; PMID:9266966; http://dx.doi.org/10.1038/sj.onc.1201241. (Pubitemid 27390132)
8. Ostrander JH, Daniel AR, Lofgren K, Kleer CG, Lange CA. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res 2007; 67:4199-209; PMID:17483331; http://dx.doi.org/10.1158/0008-5472.CAN-06-3409. (Pubitemid 46815066)
9. Lee ST, Strunk KM, Spritz RA. A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes. Oncogene 1993; 8:3403-10; PMID:8247543. (Pubitemid 23342639)
10. Mitchell PJ, Barker KT, Martindale JE, Kamalati T, Lowe PN, Page MJ, et al. Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene 1994; 9:2383-90; PMID:8036022. (Pubitemid 24228691)
11. Siyanova EY, Serfas MS, Mazo IA, Tyner AL. Tyrosine kinase gene expression in the mouse small intestine. Oncogene 1994; 9:2053-7; PMID:8208550. (Pubitemid 24194173)
12. Qiu H, Miller WT. Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition. J Biol Chem 2002; 277:34634-41; PMID:12121988; http://dx.doi.org/10.1074/jbc.M203877200.
13. Serfas MS, Tyner AL. Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases. Oncol Res 2003; 13:409-19; PMID:12725532. (Pubitemid 38166373)
14. Harvey AJ, Crompton MR. Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. Oncogene 2003; 22:5006-10; PMID:12902983; http://dx.doi.org/10. 1038/sj.onc.1206577. (Pubitemid 37026399)
15. Harvey AJ, Crompton MR. The Brk protein tyrosine kinase as a therapeutic target in cancer: opportunities and challenges. Anticancer Drugs 2004; 15:107-11; PMID:15075665; http://dx.doi.org/10.1097/00001813-200402000-00002. (Pubitemid 38316742)
16. Haegebarth A, Heap D, Bie W, Derry JJ, Richard S, Tyner AL. The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2. J Biol Chem 2004; 279:54398-404; PMID:15471878; http://dx.doi.org/10.1074/jbc.M409579200. (Pubitemid 40053179)
17. Derry JJ, Richard S, Valderrama Carvajal H, Ye X, Vasioukhin V, Cochrane AW, et al. Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding ability. Mol Cell Biol 2000; 20:6114-26; PMID:10913193; http://dx.doi.org/10.1128/MCB.20.16.6114-6126.2000. (Pubitemid 30613059)
18. Lukong KE, Larocque D, Tyner AL, Richard S. Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression. J Biol Chem 2005; 280:38639-47; PMID:16179349; http://dx.doi.org/ 10.1074/jbc.M505802200. (Pubitemid 43853766)
19. Liu L, Gao Y, Qiu H, Miller WT, Poli V, Reich NC. Identification of STAT3 as a specific substrate of breast tumor kinase. Oncogene 2006; 25:4904-12; PMID:16568091; http://dx.doi.org/10.1038/sj.onc.1209501. (Pubitemid 44201181)
20. Weaver AM, Silva CM. Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6. Breast Cancer Res 2007; 9:R79; PMID:17997837; http://dx.doi.org/10.1186/bcr1794.
21. Mitchell PJ, Sara EA, Crompton MR. A novel adaptorlike protein which is a substrate for the non-receptor tyrosine kinase, BRK. Oncogene 2000; 19:4273-82; PMID:10980601; http://dx.doi.org/10.1038/sj.onc.1203775.
22. Shen CH, Chen HY, Lin MS, Li FY, Chang CC, Kuo ML, et al. Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion. Cancer Res 2008; 68:7779-87; PMID:18829532; http://dx.doi.org/10.1158/0008-5472.CAN-08-0997.
23. Chen HY, Shen CH, Tsai YT, Lin FC, Huang YP, Chen RH. Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol 2004; 24:10558-72; PMID:15572663; http://dx.doi.org/10.1128/MCB.24.24. 10558-10572.2004.
24. Vasioukhin V, Tyner AL. A role for the epithelial-cellspecific tyrosine kinase Sik during keratinocyte differentiation. Proc Natl Acad Sci U S A 1997; 94:14477-82; PMID:9405638; http://dx.doi.org/10.1073/pnas.94.26.14477. (Pubitemid 28041399)
25. Zhang P, Ostrander JH, Faivre EJ, Olsen A, Fitzsimmons D, Lange CA. Regulated association of protein kinase B/Akt with breast tumor kinase. J Biol Chem 2005; 280:1982-91; PMID:15539407; http://dx.doi.org/10.1074/jbc.M412038200.
26. Qiu H, Zappacosta F, Su W, Annan RS, Miller WT. Interaction between Brk kinase and insulin receptor substrate-4. Oncogene 2005; 24:5656-64; PMID:15870689; http://dx.doi.org/10.1038/sj.onc.1208721. (Pubitemid 43119359)
27. Li X, Lu Y, Liang K, Hsu JM, Albarracin C, Mills GB, et al. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene 2012; 31:4372-83; PMID:22231447; http://dx.doi.org/10.1038/onc.2011.608.
28. Kamalati T, Jolin HE, Mitchell PJ, Barker KT, Jackson LE, Dean CJ, et al. Brk, a breast tumor-derived nonreceptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem 1996; 271:30956-63; PMID:8940083; http://dx.doi. org/10.1074/jbc.271.48.30956. (Pubitemid 26404123)
29. Kamalati T, Jolin HE, Fry MJ, Crompton MR. Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation. Oncogene 2000; 19:5471-6; PMID:11114724; http://dx.doi.org/10.1038/sj.onc.1203931. (Pubitemid 32000914)
30. Born M, Quintanilla-Fend L, Braselmann H, Reich U, Richter M, Hutzler P, et al. Simultaneous overexpression of the Her2/neu and PTK6 tyrosine kinases in archival invasive ductal breast carcinomas. J Pathol 2005; 205:592-6; PMID:15685689; http://dx.doi. org/10.1002/path.1720. (Pubitemid 40514832)
31. Xiang B, Chatti K, Qiu H, Lakshmi B, Krasnitz A, Hicks J, et al. Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proc Natl Acad Sci U S A 2008; 105:12463-8; PMID:18719096; http://dx.doi.org/10.1073/pnas. 0805009105.
32. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117:927-39; PMID:15210113; http://dx.doi.org/10.1016/j. cell.2004.06.006. (Pubitemid 38798858)
33. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002; 3:155-66; PMID:11994736; http://dx.doi.org/10.1038/ nrm757.
34. Bromberg J. Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res 2000; 2:86-90; PMID:11250696; http://dx.doi.org/10.1186/bcr38. (Pubitemid 32223569)
35. Clevenger CV. Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 2004; 165:1449-60; PMID:15509516; http://dx.doi. org/10.1016/S0002-9440(10)63403-7. (Pubitemid 39435145)
36. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002; 109:1139-42; PMID:11994401. (Pubitemid 34496590)
37. Gao SP, Bromberg JF. Touched and moved by STAT3. Sci STKE 2006; 2006:pe30; PMID:16835434; http://dx.doi.org/10.1126/stke.3432006pe30.
38. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7:131-42; PMID:16493418; http://dx.doi. org/10.1038/nrm1835. (Pubitemid 43278296)
39. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172:973-81; PMID:16567498; http://dx.doi. org/10.1083/jcb.200601018.
40. Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, Gerald WL, et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 2007; 9:R32; PMID:17531096; http://dx.doi. org/10.1186/bcr1680.
41. Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2003; 2:1113-20; PMID:14617784.
42. Liu B, Fang M, Schmidt M, Lu Y, Mendelsohn J, Fan Z. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer 2000; 82:1991-9; PMID:10864208. (Pubitemid 30326461)
43. Li X, Luwor R, Lu Y, Liang K, Fan Z. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTENdeficient cancer cells. Oncogene 2006; 25:525-35; PMID:16170346. (Pubitemid 43164463)